Reported about 5 hours ago
CEO Lars Jørgensen of Novo Nordisk stated that the company is not troubled by the impending 25% tariffs on pharmaceuticals amidst the US trade war. Emphasizing Novo's global manufacturing strategy, he pointed out that their active pharmaceutical ingredients are produced in the US and Denmark, allowing flexibility in distribution and local production to mitigate tariff impacts.
Source: YAHOO